Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A. Jacot W, et al. Among authors: lefeuvre c. Int J Cancer. 2019 Dec 15;145(12):3359-3369. doi: 10.1002/ijc.32402. Epub 2019 Jun 20. Int J Cancer. 2019. PMID: 31087564
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F. Cabel L, et al. Among authors: lefeuvre c. Breast Cancer Res Treat. 2019 Jan;173(2):397-406. doi: 10.1007/s10549-018-5017-2. Epub 2018 Oct 24. Breast Cancer Res Treat. 2019. PMID: 30357526
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H. André F, et al. Among authors: lefeuvre c. Lancet Oncol. 2014 Mar;15(3):267-74. doi: 10.1016/S1470-2045(13)70611-9. Epub 2014 Feb 7. Lancet Oncol. 2014. PMID: 24508104 Clinical Trial.
Genomic characterization of metastatic breast cancers.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Bertucci F, et al. Among authors: lefeuvre c. Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Nature. 2019. PMID: 31118521
Author Correction: Genomic characterization of metastatic breast cancers.
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F. Bertucci F, et al. Among authors: lefeuvre c. Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3. Nature. 2019. PMID: 31308536
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, Cutuli B, Lasry S, Mauriac L, Granon C, Kerr C, Giard S, Hill C, de Lafontan B, de Gislain C, D'Anjou J, Fondrinier E, Lefeuvre C, Parache RM, Chauvin F. Mignotte H, et al. Among authors: lefeuvre c. Int J Cancer. 1998 May 4;76(3):325-30. doi: 10.1002/(sici)1097-0215(19980504)76:3<325::aid-ijc7>3.0.co;2-x. Int J Cancer. 1998. PMID: 9579567
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Pivot X, et al. Ann Oncol. 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdu364. Epub 2014 Jul 28. Ann Oncol. 2014. PMID: 25070545 Free article. Clinical Trial.
Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V. Lesimple T, et al. Among authors: lefeuvre c. Clin Cancer Res. 2006 Dec 15;12(24):7380-8. doi: 10.1158/1078-0432.CCR-06-1879. Clin Cancer Res. 2006. PMID: 17189411 Clinical Trial.
91 results